Definium Therapeutics, Inc. (DFTX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $21.90: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Definium Therapeutics is a clinical-stage biopharmaceutical company developing pharmaceutically optimized psychedelic and empathogen compounds for brain health disorders, with lead candidates DT120 ODT in Phase 3 trials for GAD and MDD and DT402 for autism spectrum disorder. No... Read more
Sell if holding. Engine safety override at $21.90: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 48 mid-range, Bollinger mid-band. Score 5.0/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineDT120 ODT10-K Item 1A: 'We are a clinical-stage biopharmaceutical company with a limited operating history... Our most advanced development candidate is DT120 ODT.'
Material Events(8-K, last 90d)
- 2026-01-29Item 5.02LOWRoger Adsett appointed to Board of Directors effective January 29, 2026. Will receive $40,000/year and initial stock option grant. No committee assignment. No disagreement cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $21.90: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 48 mid-range, Bollinger mid-band. Prior stop was $20.42. Score 5.0/10, moderate confidence.
Take-profit target: $34.98 (+59.3% upside). Prior stop was $20.42. Stop-loss: $20.42.
Concentration risk — Pipeline: DT120 ODT; Quality below floor (1.8 < 4.0).
Definium Therapeutics, Inc. trades at a P/E of N/A (forward -12.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts cover DFTX with a consensus score of 4.3/5. Average price target: $39.
What does Definium Therapeutics, Inc. do?Definium Therapeutics is a clinical-stage biopharmaceutical company developing pharmaceutically optimized psychedelic...
Definium Therapeutics is a clinical-stage biopharmaceutical company developing pharmaceutically optimized psychedelic and empathogen compounds for brain health disorders, with lead candidates DT120 ODT in Phase 3 trials for GAD and MDD and DT402 for autism spectrum disorder. No products are approved and no revenue has been generated; cash runway expected into 2028.